product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human Gas6 Protein, CF
catalog :
885-GSB-050
quantity :
50 ug (also 500 ug)
price :
496 USD
more info or order :
citations: 39
Reference
Demirsoy S, Tran H, Liu J, Li Y, Yang S, Aregawi D, et al. Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition. Cancers (Basel). 2024;16: pubmed publisher
Lahey K, Varsanyi C, Wang Z, Aquib A, Gadiyar V, Rodrigues A, et al. Regulation of Mertk Surface Expression via ADAM17 and γ-Secretase Proteolytic Processing. Int J Mol Sci. 2024;25: pubmed publisher
Lundquist M, Jaffrey S. Gas6-Axl Signaling Induces SRF/MRTF-A Gene Transcription via MICAL2. Genes (Basel). 2023;14: pubmed publisher
Nguyen L, Aprico A, Nwoke E, Walsh A, Blades F, Avneri R, et al. Mertk-expressing microglia influence oligodendrogenesis and myelin modelling in the CNS. J Neuroinflammation. 2023;20:253 pubmed publisher
Serwe G, Kachaner D, Gagnon J, Plutoni C, Lajoie D, Duram xe9 E, et al. CNK2 promotes cancer cell motility by mediating ARF6 activation downstream of AXL signalling. Nat Commun. 2023;14:3560 pubmed publisher
Tsugawa H, Ohki T, Tsubaki S, Tanaka R, Matsuzaki J, Suzuki H, et al. Gas6 ameliorates intestinal mucosal immunosenescence to prevent the translocation of a gut pathobiont, Klebsiella pneumoniae, to the liver. PLoS Pathog. 2023;19:e1011139 pubmed publisher
Hedrich V, Breitenecker K, Ortmayr G, Pupp F, Huber H, Chen D, et al. PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma. Cancers (Basel). 2023;15: pubmed publisher
Kim J, Nam G, Shin Y, Vilaplana Lopera N, Jeung H, Moon E, et al. Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis. Cancers (Basel). 2023;15: pubmed publisher
Iida M, McDaniel N, Kostecki K, Welke N, Kranjac C, Liu P, et al. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022;22:447 pubmed publisher
Puddu A, Ravera S, Panfoli I, Bertola N, Maggi D. High Glucose Impairs Expression and Activation of MerTK in ARPE-19 Cells. Int J Mol Sci. 2022;23: pubmed publisher
Sun L, Kao S, Yang S, Jhang S, Lin Y, Chen C, et al. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis. Cells. 2021;10: pubmed publisher
Chang H, An R, Li X, Lang X, Feng J, Lv M. Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells. Oncol Lett. 2021;22:749 pubmed publisher
Wu X, Wang L, Pearson N, Renuse S, Cheng R, Liang Y, et al. Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network. Cancers (Basel). 2021;13: pubmed publisher
Pietrobono S, Anichini G, Sala C, Manetti F, Almada L, Pepe S, et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nat Commun. 2020;11:5865 pubmed publisher
Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai T, et al. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. Cell Death Differ. 2021;28:1284-1300 pubmed publisher
Xue J, Xu L, Zhu H, Bai M, Li X, Zhao Z, et al. CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK. Arthritis Res Ther. 2020;22:221 pubmed publisher
Abu Thuraia A, Goyette M, Boulais J, Delliaux C, Apcher C, Schott C, et al. AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network. Nat Commun. 2020;11:3586 pubmed publisher
Alivernini S, Macdonald L, Elmesmari A, Finlay S, Tolusso B, Gigante M, et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat Med. 2020;26:1295-1306 pubmed publisher
Hara T, Kimura A, Miyazaki T, Tanaka H, Morimoto M, Nakai K, et al. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor. Biochem Biophys Rep. 2020;21:100726 pubmed publisher
Hoj J, Mayro B, Pendergast A. A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. Cell Rep. 2019;29:3421-3434.e8 pubmed publisher
De Silva D, Zhang Z, Liu Y, Parker J, Xu C, Cai L, et al. Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. Sci Rep. 2019;9:18637 pubmed publisher
Tutusaus A, de Gregorio E, Cucarull B, Cristóbal H, Aresté C, Graupera I, et al. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cell Mol Gastroenterol Hepatol. 2020;9:349-368 pubmed publisher
Azad T, Nouri K, Janse van Rensburg H, Maritan S, Wu L, Hao Y, et al. A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis. Oncogene. 2020;39:334-355 pubmed publisher
Strange D, Jiyarom B, Pourhabibi Zarandi N, Xie X, Baker C, Sadri Ardekani H, et al. Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human Sertoli Cells. MBio. 2019;10: pubmed publisher
Duan Y, Hu B, Qiao C, Luo L, Li X, Wang J, et al. Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration. Oncol Lett. 2019;17:5784-5792 pubmed publisher
Collina F, La Sala L, Liotti F, Prevete N, La Mantia E, Chiofalo M, et al. AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer. Cancers (Basel). 2019;11: pubmed publisher
Mills K, Quinn J, Roach S, Palisoul M, Nguyen M, Noia H, et al. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Sci Rep. 2019;9:4762 pubmed publisher
Sinik L, Minson K, Tentler J, Carrico J, Bagby S, Robinson W, et al. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. Mol Cancer Ther. 2019;18:278-288 pubmed publisher
Cheng L, Chen Y, Cheng A, Lee A, Cho C, Huang J, et al. AXL phosphorylates and up-regulates TNS2 and its implications in IRS-1-associated metabolism in cancer cells. J Biomed Sci. 2018;25:80 pubmed publisher
Fujita K, Chen X, Homma H, Tagawa K, Amano M, Saito A, et al. Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. Nat Commun. 2018;9:433 pubmed publisher
Nidetz N, Gallagher T, Wiethoff C. Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding. Virology. 2018;515:150-157 pubmed publisher
Dantas Barbosa C, Lesluyes T, Loarer F, Chibon F, Treilleux I, Coindre J, et al. Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. Br J Cancer. 2017;117:1787-1797 pubmed publisher
Cross S, Potter J, Aldo P, Kwon J, Pitruzzello M, Tong M, et al. Viral Infection Sensitizes Human Fetal Membranes to Bacterial Lipopolysaccharide by MERTK Inhibition and Inflammasome Activation. J Immunol. 2017;199:2885-2895 pubmed publisher
Palisoul M, Quinn J, Schepers E, Hagemann I, Guo L, Reger K, et al. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. Mol Cancer Ther. 2017;16:2881-2891 pubmed publisher
Xu L, Chen Y, Dutra Clarke M, Mayakonda A, Hazawa M, Savinoff S, et al. BCL6 promotes glioma and serves as a therapeutic target. Proc Natl Acad Sci U S A. 2017;114:3981-3986 pubmed publisher
Kasikara C, Kumar S, Kimani S, Tsou W, Geng K, Davra V, et al. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression. Mol Cancer Res. 2017;15:753-764 pubmed publisher
de Polo A, Luo Z, Gerarduzzi C, Chen X, Little J, Yuan Z. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex. J Mol Cell Biol. 2017;9:154-165 pubmed publisher
Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït Arsa I, et al. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin Cancer Res. 2017;23:2806-2816 pubmed publisher
Happonen K, Tran S, Mörgelin M, Prince R, Calzavarini S, Angelillo Scherrer A, et al. The Gas6-Axl Protein Interaction Mediates Endothelial Uptake of Platelet Microparticles. J Biol Chem. 2016;291:10586-601 pubmed publisher
product information
brand :
R&D Systems
master code :
885-GSB
SKU :
885-GSB-050
product name :
Recombinant Human Gas6 Protein, CF
unit size :
50 ug (also 500 ug)
seo description :
The Recombinant Human Gas6 Protein, CF from R&D Systems is derived from NS0. The Recombinant Human Gas6 Protein, CF has been validated for the following applications: Bioactivity.
target :
Gas6
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 ╡m filtered solution in Tris, NaCl and Citrate.
conjugate :
Unconjugated
dilution :
Bioactivity
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.
species :
Human
observed molecular weight :
70-85 kDa, reducing conditions
theoretical molecular weight :
70.5 kDa
gene symbol :
GAS6
details of functionality :
Measured by its ability to down regulate the expression of Axl in DU145 human prostate carcinoma cells. Mishra, A. etáal . (2012) Mol. Cancer Res. 10 :703. The ED50 for this effect is 25-150 ng/mL
endotoxin note :
<1.0 EU per 1 ╡g of the protein by the LAL method.
top caption :
Graph showing bioactivity of recombinant human GAS6
accessionNumbers :
NP_000811
applications :
Bioactivity
source :
NS0-derived Recombinant Human Gas6 Protein, CF
USD :
496 USD
alt names :
AXLLG, AXLLGAXL stimulatory factor, AXSFAXL receptor tyrosine kinase ligand, DKFZp666G247, FLJ34709, GAS-6, growth arrest-specific 6, growth arrest-specific protein 6
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.
more info or order :
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.